19 Jan 2024 Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development Investors | Therapeutics
13 Dec 2023 ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data Investors | Therapeutics
05 Oct 2023 Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Investors | Therapeutics
19 Sep 2023 Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update Investors | Therapeutics
21 Jun 2023 Successful Completion of Fifth Dose Escalation in AVA6000 Phase 1 Clinical Study Investors | Therapeutics
05 Jun 2023 Avacta Achieves Second Milestone in AffyXell Joint Venture Triggering Increased Equity Stake Investors | Therapeutics